Targovax ASA: Invitation to Targovax's fourth quarter 2022 presentation, Thursday 16 February

08 Feb 2023 07:00 CET

Oslo, Norway, 8 February 2023 - Targovax ASA (OSE: TRVX) will announce its
fourth quarter 2022 results on Thursday 16 February 2023. Targovax's management
will present the results at a live streamed webcast at 10:00 am CET to
investors, analysts and the press.

The results report and the presentation will be available at
www.targovax.com (https://www.targovax.com/en/financial-reports/) in the
Investors section from 07:00 am CET, on 16 February 2023.

Presentation

There will be a virtual presentation of the results with a live webcast 16
February at 10.00 am CET. You can join the webcast
here (https://channel.royalcast.com/landingpage/hegnarmedia/20230216_12/). It
will be possible to ask questions during the presentation.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and to bring benefit to
cancer patients with few available treatment alternatives. Targovax is
developing its product candidates in different cancer indications, including
melanoma, mesothelioma, and multiple myeloma, and has demonstrated a favorable
safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system against the tumor. Following very
encouraging clinical data in several indications, both as monotherapy and in
combinations, ONCOS-102 is progressing into a randomized phase 2 trial in
melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Building on successful clinical studies which have provided deep mechanistic
insights into the tumor biology and the human immune systems, Targovax is
researching circular RNA (circRNA) as novel cancer medicines. In addition,
Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate,
TG01, expected to enter the clinic in an enhanced format in the second half of
2022.  Together this provides Targovax with a rich pipeline of innovative future
immunotherapy product candidates to follow ONCOS-102.

More information:
Access the news on Oslo Bors NewsWeb site